Prologue Medicines is leveraging the vast potential of the viral proteome to develop innovative therapeutic solutions. Their approach centers on the systematic exploration of viral proteins, which are known to evolve in response to their host's biology, offering a rich source of candidates for drug discovery. The company employs its proprietary Decoding Evolutionary Logic of Variant Ensembles (DELVE)™ Platform, a sophisticated system that integrates computational analysis with high-throughput biology. This platform enables Prologue to mine a comprehensive database of viral protein structures, facilitating the identification of proteins that can modulate human physiology and potentially treat various diseases.

The DELVE Platform operates through a multi-step process: discovery, testing, design, and learning. Initially, it uncovers complex relationships between genes, proteins, and diseases, generating insights that guide the identification of promising viral proteins. Once identified, these proteins undergo rigorous characterization to understand their interactions with human biology. Prologue then applies principles of natural viral evolution to engineer novel therapeutic proteins, enhancing their properties for therapeutic use. The iterative feedback loop from validated proteins further refines their predictive models, accelerating the discovery of new medicines. This innovative approach positions Prologue Medicines at the forefront of viral protein-based therapeutic development.

United States

Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.

Prologue Medicines

Company Details